the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title Safety Study of MGA271 in Refractory Cancer
Official Title A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Principal Investigator Szmulewitz, Russell
Brief Summary The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.
Gender Both
Ages 18 Years
Enrollment 151
Accepts Healthy Volunteers No
Lead Sponsor MacroGenicsIndustry
Study Design Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Phase Phase 1
Study Type Interventional
Contact Name Bartosz Chmielowski, MD, PhD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Prostate Cancer
Detail for Health Professional (on
More clinical trials by this PI